PathoSyn: Disentangled Pathological Modeling

• PathoSyn is a framework that disentangles complex pathological trajectories and imaging data into interpretable components.
• It employs dynamic pathosome models, GAN-based pseudo-healthy synthesis, and time-series path signatures to capture both temporal and spatial disease dynamics.
• Empirical benchmarks show improved predictive accuracy and realistic image synthesis, demonstrating its potential in clinical applications.

The PathoSyn approach encompasses a constellation of methodologies for disentangled modeling, analysis, and synthesis of pathological trajectories and imaging data. These frameworks share a unifying objective: to separate and exploit the underlying “synergistic” structure of pathological processes, whether in time-resolved phenotypic progression, multimodal imaging, or disease network dynamics. The concept has been instantiated in multiple technical fields, including longitudinal data analysis, medical image synthesis, time-ordered biomarker signatures, and systems medicine. Core implementations include dynamic pathosome models for temporal data, pathology/disentanglement GANs, deviation-space diffusion on MR imaging, and network synergy in Alzheimer’s disease.

1. Mathematical Foundations of the PathoSyn Approach

The PathoSyn paradigm is grounded in explicit factorization and disentanglement of trajectory or image data into interpretable components. In time-resolved analyses, PathoSyn models longitudinal scalar responses $Y_i$ as functionals of historical molecular or phenotypic trajectories:

$$Y_i = \alpha + \int_T X_i(t)\,\beta(t)\,dt + \epsilon_i$$

where $X_i(t)$ is a fully functional predictor (e.g., growth curve or biomarker history), $\beta(t)$ is a coefficient function encoding time-dependent effect size, and $\epsilon_i$ is i.i.d. noise. Extensions include multivariate predictors, additional scalar covariates, and hybrid function-on-scalar models (Lenart et al., 2021).

In imaging, PathoSyn frameworks decompose an observed pathological image $x$ into an anatomical substrate $x_{sub}$ (structural baseline) and a spatially localized residual $r$ (pathological deviation):

$x = x_{sub} + r, \qquad r \sim p(r\,|\,x_{sub}, m)$

where $m$ is a lesion mask. This conditional generative model targets $$Y_i = \alpha + \int_T X_i(t)\,\beta(t)\,dt + \epsilon_i$$0 via deviation-space diffusion, separating stochastic lesion content from deterministic anatomy (Wang et al., 29 Dec 2025).

“Pseudo-healthy” synthesis instantiations separate “healthy” appearance $$Y_i = \alpha + \int_T X_i(t)\,\beta(t)\,dt + \epsilon_i$$1 and pathology mask $$Y_i = \alpha + \int_T X_i(t)\,\beta(t)\,dt + \epsilon_i$$2 from $$Y_i = \alpha + \int_T X_i(t)\,\beta(t)\,dt + \epsilon_i$$3 and leverage adversarial or reconstruction cycles to maintain subject identity:

$$Y_i = \alpha + \int_T X_i(t)\,\beta(t)\,dt + \epsilon_i$$4

where $$Y_i = \alpha + \int_T X_i(t)\,\beta(t)\,dt + \epsilon_i$$5 synthesizes healthy images, $$Y_i = \alpha + \int_T X_i(t)\,\beta(t)\,dt + \epsilon_i$$6 segments pathology, and $$Y_i = \alpha + \int_T X_i(t)\,\beta(t)\,dt + \epsilon_i$$7 reconstructs $$Y_i = \alpha + \int_T X_i(t)\,\beta(t)\,dt + \epsilon_i$$8 (Xia et al., 2019, Xia et al., 2020).

In time-series biomarker modeling, iterated path signatures offer an algebraic encoding:

$$Y_i = \alpha + \int_T X_i(t)\,\beta(t)\,dt + \epsilon_i$$9

where $X_i(t)$0 is a multivariate trajectory (e.g., brain, hippocampal, ventricular volumes plus time) and degree-2 truncation ensures fixed feature dimension regardless of sampling irregularities (Moore et al., 2018).

For systems-medicine synergy, network ODEs formalize feedback among multiple pathologies:

$X_i(t)$1

where $X_i(t)$2, $X_i(t)$3, $X_i(t)$4 represent amyloid, tau, and inflammation (She, 4 Dec 2025).

2. Algorithmic Implementation and Estimation Strategies

In longitudinal scalar-on-function models, estimation proceeds via basis expansion:

$X_i(t)$5

and penalized least squares with roughness regularization:

$X_i(t)$6

tuning basis dimension and $X_i(t)$7 by GCV, AIC/BIC, or K-fold CV. Denser observation sampling and cubic B-spline bases enable sharper time localization of effects (Lenart et al., 2021).

In pseudo-healthy image synthesis, adversarial cycles are coupled with explicit disentanglement losses, reconstruction constraints, and mask-based discrimination. Training alternates between paired (Dice loss on mask) or unpaired (mask adversarial loss), utilizing Adam optimization and multi-task weighting (Xia et al., 2019, Xia et al., 2020).

Deviation-space diffusion in imaging is realized as a masked denoising diffusion process, regularized by seam-aware fusion and boundary penalties:

$X_i(t)$8

Inference applies both mask and transition blending at every denoising step (Wang et al., 29 Dec 2025).

Time-series path signature approaches construct piecewise-linear paths, compute truncated signatures up to degree 2 (yielding 20-dim nonlinear features), and fit Lasso-penalized logistic models with cross-validation for predictor selection (Moore et al., 2018).

3. Critical Time-Window and Feature Interpretability

The PathoSyn approach emphasizes the localization of temporal or spatial windows where contributions to the outcome are strongest.

In dynamic pathosome modeling, estimation of $X_i(t)$9 allows identification of critical sub-intervals $\beta(t)$0 via confidence bands; representative time points $\beta(t)$1 are extracted where $\beta(t)$2 is maximal. Scalar models fitted to $\beta(t)$3 (using these times) achieve $\beta(t)$4 nearly as high as the full functional model, enhancing interpretability (Lenart et al., 2021).

For path signatures, specific area and increment terms (e.g., $\beta(t)$5—area between time and ventricle path, $\beta(t)$6—brain and hippocampus interaction) are directly interpretable biomarkers, indicating not only the magnitude but the sequence and coupling of pathological changes—reducing reliance on handcrafted nonlinear terms (Moore et al., 2018).

In imaging, spatial disentanglement allows visual and quantitative demarcation of lesions versus healthy tissue, further used for anomaly detection, segmentation improvement, and data augmentation (Wang et al., 29 Dec 2025, Xia et al., 2019, Xia et al., 2020).

4. Empirical Results and Comparative Benchmarks

Comparative studies have demonstrated the empirical advantages of PathoSyn instantiations across multiple tasks:

• For scalar-on-function modeling in phenotype prediction (e.g., age at menarche), functional models (height and weight trajectories) achieve $\beta(t)$7 (vs $\beta(t)$8 for the best classical linear model) (Lenart et al., 2021).
• In imaging, PathoSyn achieves higher pseudo-healthy image realism and anatomical fidelity than conditional GAN and CycleGAN baselines, with identity (MS-SSIM) $\beta(t)$9 (BraTS paired) and healthiness $\epsilon_i$0 (BraTS paired); ISLES paired: identity $\epsilon_i$1, healthiness $\epsilon_i$2 (Xia et al., 2019).
• Deviation-space diffusion models yield improved downstream segmentation (nnU-Net Dice $\epsilon_i$3 vs $\epsilon_i$4), lower classifier calibration error, and indistinguishable realism relative to real MRI by binary discrimination (AUC $\epsilon_i$5 vs $\epsilon_i$6 for holistic diffusers) (Wang et al., 29 Dec 2025).
• In AD biomarker signature studies, path signature features selected by Lasso correspond to canonical progression patterns (ventricular baseline and increment, hippocampal shrinkage), supporting both interpretability and robust feature selection even with missing/irregular data (Moore et al., 2018).

5. Practical Guidance and Implementation Recommendations

Recommended practices for PathoSyn methodologies are as follows:

• For functional linear modeling, ensure sample size exceeds $\epsilon_i$7(basis functions). Prefer B-splines for localized effects; Fourier for periodic trajectories. Penalize second derivative of $\epsilon_i$8 for smoothness. Use GCV for smoothing parameter selection in moderate/large samples, but K-fold CV for small $\epsilon_i$9. R package “fda” is standard for implementation, though custom confidence interval or $x$0 estimation may be needed (Lenart et al., 2021).
• In image-based PathoSyn, high performance is achieved even with unpaired mask training, though paired regimes yield moderate segmentation and realism gains. Architectural choices (e.g., ResNet blocks, U-net segmentors, PatchGAN discriminators) and WGAN-GP objectives yield sharper corrections and preserve both identity and anatomical semantics compared to vanilla or cycle-GANs (Xia et al., 2020, Xia et al., 2019).
• For deviation-diffusion MRI synthesis, maintain a strict lesion-mask constraint throughout both training and inference, and use seam-aware fusion to prevent boundary artifacts. For data augmentation, generate digital twins by varying lesion masks and residual noise, supporting counterfactual explorations.
• In systems synergy models for disease, intervention timing is essential: efficacy is highest before the nonlinear feedback regime (proximal to “critical” cross-talk thresholds); combinatorial therapy arms should be stratified by multimodal biomarkers (e.g., AT(N)I framework) and AI-guided clustering (She, 4 Dec 2025).

6. Applications, Limitations, and Future Directions

PathoSyn models are leveraged in diverse translational pipelines:

• Trajectory-based predictions in developmental epidemiology and growth studies, identifying key developmental windows (Lenart et al., 2021).
• High-fidelity, anatomically faithful pseudo-healthy image generation for medical imaging anomaly detection, segmentation, and data augmentation, with counterfactual progression modeling via lesion mask perturbation (Wang et al., 29 Dec 2025, Xia et al., 2019, Xia et al., 2020).
• Time-ordered feature extraction via path signatures, robust to missing or irregular data, yielding interpretable, disease-relevant features in neurodegenerative biomarker time-series (Moore et al., 2018).
• Systems medicine frameworks for Alzheimer’s disease connecting amyloid, tau, and neuroinflammatory pathologies, predicting that multi-target adaptive therapies—deployed in biomarker-guided, AI-stratified trials—are essential for disease modification (She, 4 Dec 2025).

Limitations include the assumption of anatomical stability in imaging paradigms (global deformities not explicitly modeled), proxy metrics for subjective identity/realism, noise sensitivity at sparse sampling regimes, and the need for accurate segmentation masks or mask discriminators. Open challenges involve extension to higher-dimensional imaging (3D/4D), disentangling multiple overlapping pathologies, and deployment of adaptive, biomarker-driven clinical trial architectures.

In summary, the PathoSyn approach operationalizes the principle that pathological complexity is best modeled via explicit, interpretable factorization of trajectory and imaging data, allowing rigorous localization, prediction, and generative manipulation that consistently enhances the scientific and clinical utility of downstream analyses (She, 4 Dec 2025, Wang et al., 29 Dec 2025, Lenart et al., 2021, Xia et al., 2020, Xia et al., 2019, Moore et al., 2018).